| Característica |
Objectiu de la convocatòria
The Alzheimer's Drug Discovery Foundation supports promising, diverse international research projects to develop new drugs for Alzheimer's and related dementias, including vascular, Lewy body, and frontotemporal dementias.
ADDF's goal is to fill the critical translational funding gap that exists between basic research and later-stage drug development. ADDF funds three categories of research:
Drug discovery and preclinical development, including high throughput screening, medicinal chemistry, lead optimization, in vivo efficacy, safety and toxicology, formulation of the drug, and scale-up
Clinical trials
Early detection, such as biomarkers and neuroimaging
|
Característiques principals
FUNDING MECHANISMS:
Preclinical Drug Discovery RFP: promising preclinical drug discovery and biomarker development programs relevant to Alzheimer's disease, other dementias and cognitive ageing.
Program to Accelerate Clinical Trials (PACT) RFP: exploratory Phase 0 microdosing studies that assess preliminary target engagement and PK, Phase I safety testing, Phase 2 biomarker-based proof-of-concept clinical trials in patients, as well as IND-enabling studies to accelerate new drugs into trials.
NEW FUNDING MECHANISMS FROM JUNE 2017:
Biomarkers Development RFP: Seeks to support the development and validation of novel and existing biomarkers that will enhance the design and performance of clinical trials for Alzheimer's disease, related dementias, and cognitive aging.
Prevention Beyond the Pipeline RFP:Seeks to support prevention drug development not covered by most research funders or our current RFPs.
|
Lloc de presentació
El personal de l'IMIM i PSMAR que necessiteu més informació adreceu-vos a:
Servei de Recerca. C/ Doctor Aiguader, 88. 08003-Barcelona. Tel.: 93.316.05.76.
Marta López: mlopez4@imim.es Ext.: 1576
Carol Barnwell: cbarnwell@imim.es Ext.: 1670
|
Convocatòria (URL)
http://www.alzdiscovery.org/research-and-grants/funding-opportunities
|
Dotació
Preclinical drug discovery: average award $150.000-$600.000
Program to accelerate clinical trials : average award up to $1.500.000 (increased to $3.000.000)
|
Durada
Preclinical drug discovery: 1-2 years
Program to accelerate clinical trials : varies
|
AVÍS IMPORTANT
Deadlines for 2017 RFPs:
March 10,
June 9,
September 8,
December 8
***Letters of intent are due at least two weeks prior to each deadline.***
Deadlines for letters of intent have been updated:
Jul 31 for RFP deadline Sep 8
Nov 17 for RFP deadline Dec 8
|